Alvogen

Last updated
Alvogen
Company typeprivate
Founded2009
Founder Róbert Wessman
Headquarters Pine Brook, New Jersey [1]
RevenueIncrease2.svg $1.1 billion (2017)
Owners CVC Capital Partners and Temasek Holdings
Number of employees
2800
Website www.alvogen.com

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

Contents

Its sister company Alvotech produces biosimilars.

History

Alvogen was founded in 2009 by Robert Wessman, who stepped down from his position as CEO of Actavis in order to found the company. [2] [3] [4] Soon after its founding it had 200 products in development. [5] Since 2012, Alvogen has acquired three different companies in Taiwan and South Korea (Alvogen Korea), where it operates as Lotus Pharmaceuticals (which Alvogen purchased in 2014 for $200 million) and is listed on Taipei Stock Exchange (1795.TT). [6] In 2015, Alvogen acquired DreamPharma for $187 million. [7] It is also the parent company of Norwich Pharmaceuticals, which does the firm's manufacturing. [8]

In 2015, a controlling interest in Alvogen was acquired by CVC Capital Partners and the Singapore sovereign fund Temasek. As of 2017, the company had 2800 employees spread over thirty-five countries. In 2016, Alvogen also acquired the US company County Line Pharmaceuticals for $300 million. [9] In 2017, Alvogen was valued at $4 billion. [10]

Pharmaceuticals

Alvogen markets 350 different products including generic drugs, branded medicines, biosimilar products, cosmetics, and food supplements, for areas including oncology, cardiology, pulmonology, and neurology. Much of its products for European markets are manufactured at a factory in Romania, and packaged in Serbia. [10] Companies that market their products through Alvogen or have sold their generic drugs to Alvogen for sale include Bayer, [11] Mylan, [12] Natco, [13] and Pfizer. [14]

In 2017, Alvogen partnered with Vivus to provide the anti-obesity drug phentermine/topiramate to the South Korean market [15] [16] and partnered with Omega Bittner to provide products in the Russian market. [17] In 2017, Alvogen also became the first company to bring a generic oseltamivir [18] to the US market. [19] That year, Alvogen had 75 additional products under review with the FDA for approval for sale in the US market. [20]

Alvotech

Alvotech is a sister company [21] of Alvogen that researches and manufactures biosimilars. It was founded in 2013 by Alvogen founder Robert Wessman. Alvotech is based out of Iceland, and it has four research and production sites across Europe. [22] It is listed on Nasdaq [23] and had a market cap of 3.5 billion USD in 2023. [24]

Its first product, an adalimumab biosimilar, received marketing authorization in 2021, [25] and its second product, an ustekinumab biosimilar, in 2023. [26] Products under development include biosimilars of omalizumab, denosumab, golimumab, aflibercept, vedolizumab, and pembrolizumab. [27]

Controversies

In November 2022, Alvogen and a former executive settled a dispute over allegations of bullying made the previous year. [28]

In September 2021, Swedish doctor Essam Mansour, who invested $500,000 in Alvogen in 2009, accused Robert Wessman as the CEO of Alvogen of excluding him from participation in the company and of presenting his views at company meetings without his authorisation. Wessman denied doing so. [29]

Related Research Articles

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Meiji Seika Pharma</span> Japanese food and pharmaceutical company

Meiji Seika Pharma Co., Ltd., formerly Meiji Seika Kaisha, Ltd. is a Japanese pharmaceutical company. It is currently a subsidiary of Meiji Holdings and a Japanese leader in the area of infectious disease with 18% market share. It markets treatments for depression, obsessive-compulsive disorder, vaccines and allergy drugs. Meiji Pharma is doing research in generic anticancer drugs and biosimilars with partner organisations.

<span class="mw-page-title-main">Gedeon Richter (company)</span> Hungarian pharmaceutical company

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Allergan, Inc.</span> Former American conglomerate

Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. It ceased operation in 2015 when it was acquired by Irish-based Actavis plc, who then renamed the group as Allergan plc.

<span class="mw-page-title-main">Hetero Drugs</span> An Indian pharmaceutical company

Hetero Drugs is an Indian pharmaceutical company and the world's largest producer of anti-retroviral drugs. Hetero's business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

The Pharma Letter, is an English pharmaceutical, generics and biotechnology news and analysis service.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. It's market presence is more than 100+ countries.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

<span class="mw-page-title-main">Natco Pharma</span> Indian pharmaceutical company

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services. It is a major producer of branded oncology medicines and hepatitis C drugs. The company specialises in producing complex medicines at affordable prices. In 2019, Natco launched its crop health sciences division.

Wilhelm Róbert Wessman is an Icelandic business executive and founder of the pharmaceutical and biotechnology companies Alvotech and Alvogen.

References

  1. ↑ "Company Overview of Alvogen, Inc". Bloomberg. Retrieved 21 July 2018.
  2. ↑ Wessman steps down as Actavis CEO
  3. ↑ "Alvogen to buy U.S. drugmaker County Line for $300 million: sources". Reuters. 7 March 2016.
  4. ↑ Isenberg, Daniel (9 July 2013). Worthless, Impossible and Stupid: How Contrarian Entrepreneurs Create and Capture Extraordinary Value. Harvard Business Review Press. ISBN   9781422186985 – via Google Books.
  5. ↑ Strother, Judith B.; Ulijn, Jan M.; Fazal, Zohra (2 October 2012). Information Overload: An International Challenge for Professional Engineers and Technical Communicators. John Wiley & Sons. ISBN   9781118360507 – via Google Books.
  6. ↑ "Alvogen Partially Acquires Lotus Pharma For US$200 Million". 3 January 2014.
  7. ↑ "Alvogen Acquiring DreamPharma for $187M - GEN". GEN. 2014-08-06.
  8. ↑ "Norwich Pharmaceuticals, An Alvogen Company, celebrates expansion".
  9. ↑ "County Line Pharmaceuticals to be acquired by Alvogen for $300 million".
  10. 1 2 "CVC to Explore Options for $4 Billion Drugmaker Alvogen". 26 September 2017 – via www.bloomberg.com.
  11. ↑ Letter, The Pharma. "Alvogen acquires five hormonal products from Bayer". www.thepharmaletter.com.
  12. ↑ "Mylan to Sell Seven Generics to Alvogen as FTC Clears Perrigo Deal - GEN". GEN. 2015-11-04.
  13. ↑ Market, Capital (3 November 2017). "Natco's partner Alvogen to market generic Oseltamivir phosphate power for oral suspension". Business Standard India– via Business Standard.
  14. ↑ Letter, The Pharma. "Alvogen to buy product portfolio from Pfizer". www.thepharmaletter.com.
  15. ↑ "VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug". 6 September 2017.
  16. ↑ Letter, The Pharma. "Alvogen adds Qsymia to its anti-obesity portfolio in South Korea". www.thepharmaletter.com.
  17. ↑ Letter, The Pharma. "Alvogen to expand Russian business with acquisition". www.thepharmaletter.com.
  18. ↑ "Award Winner".
  19. ↑ Letter, The Pharma. "Amneal's generic Tamiflu now available in USA". www.thepharmaletter.com.
  20. ↑ "Alvogen gets US FDA nod to market antiviral drug". ehealth.eletsonline.com.
  21. ↑ "Eru ekki að selja í Alvogen". www.mbl.is (in Icelandic). Retrieved 2023-11-28.
  22. ↑ "The story of Alvogen and the founding of a pharma empire".
  23. ↑ "Alvotech skráð á markað vestanhafs". www.mbl.is (in Icelandic). Retrieved 2023-11-28.
  24. ↑ "180 milljarðar í lyfjaþróun". www.mbl.is (in Icelandic). Retrieved 2023-11-28.
  25. ↑ "Fyrsta líftæknilyf Alvotech samþykkt". www.mbl.is (in Icelandic). Retrieved 2023-11-28.
  26. ↑ "Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara (ustekinumab)". Alvotech. November 14, 2023.
  27. ↑ "Pipeline - Alvotech - Better Access Better Lives". www.alvotech.com. Retrieved 2023-11-28.
  28. ↑ "Alvogen fellur frá málsókn gegn Halldóri eftir sættir," www.ruv.is (in Icelandic). 2022-22-11.
  29. ↑ "Sænskur læknir telur Róbert hafa farið á bak við sig og selt eignir til skattaskjólsins Jersey án síns leyfis". Stundin. Retrieved 2021-09-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.